Chronic Lymphocytic Leukemia working group
Composition
Chair
Prof. Dr. A. P. Kater (AmsterdamUMC – AMC, Amsterdam)
Vice-chair
Dr. M.D. Levin (Albert Schweitzer Hospital, Dordrecht)
Secretary
Dr. D. te Raa (Gelderse Vallei, Ede)
Treasurer
Dr. R. Mous (UMCU, Utrecht)
Chief protocol
Dr. S. Kersting (Hagaziekenhuis, Den Haag)
Key objectives of working group
The key objectives of this working group are:
- To initiate and implement (inter)national multicenter phase (I/)II and III clinical studies for CLL patients
- To partner in Intergroup studies, with key partners: Nordic CLL SG, and the German CLL SG
- To partner with pharma initiated studies only if the working group has a clear and recognizable role
- To co-develop and recommend certified diagnostics in the Netherlands
- To participate in the ERIC (European Research Initiative on CLL)
- To develop guidelines for diagnosis and treatment of CLL and related disorders
- To guide reimbursement issues
- To initiate and implement healthcare innovations
CLL associated studies
A list of HOVON associated CLL studies can be found here
Research on CLL samples
For the CLL working group members it is possible to request to perform analyses on the samples taken from CLL patients and stored in the biobank. Please find below the regulations of this biobank and the usage of the samples
Publication overview
- Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial
- First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
- Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation
Meetings & Minutes
Please note the section where meetings dates & minutes are shown are only accessible after log in.
This content is restricted. Please log in.
This content is restricted. Please log in.